Phospholipase A2 inhibitors in development

Expert Opinion on Investigational Drugs

Volumn 6, Issue 3, 1997, Pages 279-298

  Tibes, U ^a   Friebe, W G ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 ACETOXYTRIDECYL) 5 HYDROXY 2(5H) FURANONE; 4 (3 CARBOXYPHENYL) 3,7 DIMETHYL 9 (2,6,6 TRIMETHYL 1 CYCLOHEXENYL) 2,4,6,8 NONATETRAENOIC ACID; ANTIINFLAMMATORY AGENT; ARL 67974; BM 162056; BM 162058; CYTOKINE; FOLIPASTATIN; FPL 67047; FREE RADICAL; ISOENZYME; LY 311727; MANOALIDE; ML 3116; N (2 ETHYLSULFONYLAMINO 5 TRIFLUOROMETHYL 3 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; RO 23 9358; SB 203347; SR 2566; SUPEROXIDE; THIELOCIN B3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 121520; WAY 125353; WAY 125984; WILD 20; YM 26567 1; YM 26734;

ACUTE PANCREATITIS; ANIMAL MODEL; ASTHMA; CATALYSIS; CYTOSOL; DRUG BIOAVAILABILITY; DRUG SELECTIVITY; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATORY DISEASE; MEDIATOR; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SKIN INFLAMMATION;

EID: 0030893303     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.3.279     Document Type: Review

References (145)